GPh 201
Alternative Names: GPh-201Latest Information Update: 25 Aug 2023
Price :
$50 *
At a glance
- Originator GEROPHARM
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Eye disorders in Russia (unspecified route) (GEROPHARM pipeline, August 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Eye-disorders in Russia
- 18 Dec 2015 Preclinical trials in Eye disorders in Russia (unspecified route) prior to December 2015 (GEROPHARM pipeline, December 2015)